This site is intended for Healthcare professionals only.

Topical propranolol effective in small infantile haemangiomas


Topical propranolol effective in small infantile haemangiomas

Infantile haemangiomas are the most common tumour of infancy which in a majority of cases involute spontaneously. The first‐line treatment of  Infantile haemangiomas is oral propranolol which has a risk of systemic adverse effects.

Price A and colleagues conducted a Systematic review and meta-analysis to investigate the role of topical preparations in Infantile haemangiomas and found that topical propranolol was effective in small, superficial haemangiomas. The findings have been published in Journal of the European Academy of Dermatology and Venereology

The researchers followed  PRISMA guidelines and searched four databases to identify original articles evaluating the use of topical propranolol as the primary therapy for infantile haemangiomas. Twelve articles with a total of 597 patients and 632 haemangiomas were included. Three topical propranolol preparations were used, creams, ointments, and gels and were all prepared by local pharmaceutical laboratories. The concentration of propranolol ranged from 0.5% to 5% and the treatment duration ranged from two weeks to 16.5 months.

The researchers found that in all, 90% of lesions improved following the initiation of topical propranolol. A good or excellent response, defined as a reduction in the size of at least 50%, was seen in 59% of lesions. Earlier initiation of treatment (less than 3 months of age) was associated with improved outcomes.

There were no systemic adverse effects with only minor local reactions in 1.3% of patients. Topical propranolol is safer than oral propranolol, though may be less effective. It may be more suitable for patients with small, superficial haemangiomas at risk of cosmetic sequelae, where the cosmetic or symptomatic impact does not warrant oral propranolol treatment.

For more details click on the link: https://doi.org/10.1111/jdv.14963

The following two tabs change content below.
Anjali Nimesh

Anjali Nimesh

Anjali Nimesh Joined Medical Dialogue as Reporter in 2016. she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Dr. Bhimrao Ambedkar University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted